Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Myriad's impact on gene patents

Nature Biotechnology volume 34, pages 1119–1123 (2016)Cite this article

Subjects

Three years later, the landmark Myriad decision on gene patents has led to some striking and unforeseen implications.

“The lawless science of our law, that codeless myriad of precedent, that wilderness of single instances...”

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1
Figure 2: Granted patents with gene-related claims containing sequence IDs, including the gene-related search terms identified in search S1 (general) and S2 (isolated) from Table 1, as well as the keyword 'isolated' within three words of 'DNA.'
Figure 3: Gene-related patents (a) filed in the last 20 years containing the S3 search terms in Table 1 and (b) including the keyword “isolated” within 3 words of DNA in the claims.

References

  1. Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).

  2. Burk, D.L. J. Law Biosci. 2, 606–626 (2015).

    PubMed  PubMed Central  Google Scholar 

  3. In re BRCA1- & BRCA2- Based Hereditary Cancer Test Patent Litig v. Ambry Genetics Corp., 774 F.3d 755 (Fed. Cir. 2014).

  4. Sherkow, J.S. & Greely, H.T. Annu. Rev. Genet. 49, 161–182 (2015).

    Article  CAS  Google Scholar 

  5. Guerrini, C.J., Majumder, M.A. & McGuire, A.L. Nat. Biotechnol. 34, 145–147 (2016).

    Article  CAS  Google Scholar 

  6. Graff, G.D. et al. Nat. Biotechnol. 31, 404–410 (2013).

    Article  CAS  Google Scholar 

  7. Gordon, J. Cold Spring Harb. Perspect. Med. 5, http://dx.doi.org/10.1101/cshperspect.a020917 (2014).

  8. Cook-Deegan, R. & Niehaus, A. Curr. Genet. Med. Rep. 2, 223–241 (2014).

    Article  Google Scholar 

  9. Woessner, W.D. & Chadwick, R.A. Pharm. Pat. Anal. 2, 165–167 (2013).

    Article  CAS  Google Scholar 

  10. Ratner, M. Nat. Biotechnol. 31, 663–665 (2013).

    Article  CAS  Google Scholar 

  11. Gold, R.E., Cook-Deegan, R. & Bubela, T. Sci. Transl. Med. 5, 192ed9 (2013).

    Article  Google Scholar 

  12. Offit, K. et al. J. Clin. Oncol. 31, 2743–2748 (2013).

    Article  Google Scholar 

  13. Bubela, T. et al. Nat. Biotechnol. 31, 202–206 (2013).

    Article  CAS  Google Scholar 

  14. Cook-Deegan, R. & Heaney, C. Annu. Rev. Genomics Hum. Genet. 11, 383–425 (2010).

    Article  CAS  Google Scholar 

  15. Hopkins, M.M., Mahdi, S., Patel, P. & Thomas, S.M. Nat. Biotechnol. 25, 185–187 (2007).

    Article  CAS  Google Scholar 

  16. 35 USC § 101.

  17. 35 USC § 102.

  18. 35 USC § 103.

  19. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012).

  20. Alice Corporation v. CLS Bank International, 132 S. Ct. 2347 (2014).

  21. Arora, A., Fosfuri, A. & Gambardella, A. Markets for Technology (MIT Press, 2001).

    Book  Google Scholar 

  22. Sichelman, T. & Graham, S.J. Mich. Telecomm. & Tech. L. Rev. 17, 111–180 (2010).

    Google Scholar 

  23. http://www.scotusblog.com/case-files/cases/association-for-molecular-pathology-v-myriad-genetics-inc/

  24. Royzman, I. Nat. Biotechnol. 33, 925–926 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mateo Aboy, Kathleen Liddell, Johnathon Liddicoat and Cristina Crespo are in the Centre of Law, Medicine, and Life Sciences (LML), Faculty of Law, University of Cambridge, Cambridge, UK.,

    Mateo Aboy, Kathleen Liddell, Johnathon Liddicoat & Cristina Crespo

  2. Mateo Aboy is also in the College of Engineering, Technology and Management, Oregon Institute of Technology, Klamath Falls, Oregon, USA.,

    Mateo Aboy

Authors
  1. Mateo Aboy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Liddell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johnathon Liddicoat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristina Crespo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mateo Aboy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figures

Supplementary Figures 1–4 (PDF 344 kb)

Supplementary Table 1

Key Empirical Research on DNA-related patent protection (PDF 146 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aboy, M., Liddell, K., Liddicoat, J. et al. Myriad's impact on gene patents. Nat Biotechnol 34, 1119–1123 (2016). https://doi.org/10.1038/nbt.3719

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3719

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing